Stocks News

LAST PRICE
0.6216
TODAY'S CHANGE (%)
Trending Up0.0171 (2.8288%)

Bid / Lots
0.6000/ 1
Ask / Lots
0.6558/ 1
Open / Previous Close
0.6000 / 0.6045
Day Range
Low 0.6000
High 0.6457
52 Week Range
Low 0.5400
High 1.7900
Volume
107,997
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Oct 24, 2024
- Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference, from 7:00AM ET on Thursday Oct 24, 2024 by Dow Jones
  7:00AM ET on Thursday Oct 24, 2024 by Dow Jones
  Companies Mentioned: PASG
  
  Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference
  
  Preclinical data demonstrated that an AAV1 vector achieved superior human progranulin levels in the CSF as compared to AAV5 and AAVhu68 (an AAV9 variant)

Today
- NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting, from 23 minutes ago by Dow Jones
  23 minutes ago by Dow Jones
  Companies Mentioned: NXTC
- Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board, from 8 hours ago by Dow Jones
  8 hours ago by Dow Jones
  Companies Mentioned: LTRN
Yesterday
- Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF- Antibodies for Idiopathic Pulmonary Fibrosis, from 8:30AM ET on Monday Nov 04, 2024 by Dow Jones
  8:30AM ET on Monday Nov 04, 2024 by Dow Jones
  Companies Mentioned: SRZN
Oct 31, 2024
- Press Release: Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET, from 8:03AM ET on Thursday Oct 31, 2024 by Dow Jones
  8:03AM ET on Thursday Oct 31, 2024 by Dow Jones
  Companies Mentioned: LTRN
- Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET, from 8:00AM ET on Thursday Oct 31, 2024 by Dow Jones
  8:00AM ET on Thursday Oct 31, 2024 by Dow Jones
  Companies Mentioned: LTRN
Oct 23, 2024
- Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024, from 8:45AM ET on Wednesday Oct 23, 2024 by Dow Jones
  8:45AM ET on Wednesday Oct 23, 2024 by Dow Jones
  Companies Mentioned: LTRN
Oct 21, 2024
- Lantern Pharma to Host & Participate in Two Public Webinars During October, from 8:00AM ET on Monday Oct 21, 2024 by Dow Jones
  8:00AM ET on Monday Oct 21, 2024 by Dow Jones
  Companies Mentioned: LTRN
Oct 15, 2024
- Lantern Pharma's Prospective Brain Tumor Therapy Gets FDA Fast Track Designation, from 10:09AM ET on Tuesday Oct 15, 2024 by MT Newswires
  10:09AM ET on Tuesday Oct 15, 2024 by MT Newswires
  Companies Mentioned: LTRN
- Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA, from 9:07AM ET on Tuesday Oct 15, 2024 by Dow Jones
  9:07AM ET on Tuesday Oct 15, 2024 by Dow Jones
  Companies Mentioned: LTRN

Passage Bio Inc
NASDAQ:PASGUnited States
NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Search Criteria

Oct 24, 2024

Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference, from 7:00AM ET on Thursday Oct 24, 2024 by Dow Jones

Peers Headlines

Today

NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting, from 23 minutes ago by Dow Jones

Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board, from 8 hours ago by Dow Jones

Yesterday

Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF- Antibodies for Idiopathic Pulmonary Fibrosis, from 8:30AM ET on Monday Nov 04, 2024 by Dow Jones

Oct 31, 2024

Press Release: Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET, from 8:03AM ET on Thursday Oct 31, 2024 by Dow Jones

Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET, from 8:00AM ET on Thursday Oct 31, 2024 by Dow Jones

Oct 23, 2024

Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024, from 8:45AM ET on Wednesday Oct 23, 2024 by Dow Jones

Oct 21, 2024

Lantern Pharma to Host & Participate in Two Public Webinars During October, from 8:00AM ET on Monday Oct 21, 2024 by Dow Jones

Oct 15, 2024

Lantern Pharma's Prospective Brain Tumor Therapy Gets FDA Fast Track Designation, from 10:09AM ET on Tuesday Oct 15, 2024 by MT Newswires

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA, from 9:07AM ET on Tuesday Oct 15, 2024 by Dow Jones